| Outcome Measures: |
Primary: Maximum observed plasma concentration (Cmax) of metformin, 0, 0.5, 1,1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Days 5 and 10|Area under the plasma concentration vs time curve over the dosing interval, at steady state (AUCtau) of metformin, 0, 0.5, 1,1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Days 5 and 10 | Secondary: Number of participants with adverse events, From time of signed informed consent to time of follow-up phone call, an expected average of 5 weeks|Maximum observed plasma concentration (Cmax) of ranolazine and metabolites, 0, 0.5, 1,1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 10|Area under the plasma concentration versus time curve over the dosing interval, at steady state (AUCtau) of ranolazine and metabolites, 0, 0.5, 1,1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 10
|
